Burney Co. Grows Stake in AstraZeneca PLC (NASDAQ:AZN)

Burney Co. grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 5.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,891 shares of the company’s stock after buying an additional 872 shares during the period. Burney Co.’s holdings in AstraZeneca were worth $1,041,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AZN. Stratos Wealth Advisors LLC raised its stake in shares of AstraZeneca by 2.0% in the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after buying an additional 133 shares during the period. Crumly & Associates Inc. raised its stake in AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after acquiring an additional 143 shares during the period. Harbour Investments Inc. lifted its holdings in AstraZeneca by 1.9% during the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after purchasing an additional 160 shares in the last quarter. Smith Salley Wealth Management increased its stake in shares of AstraZeneca by 1.0% in the third quarter. Smith Salley Wealth Management now owns 16,158 shares of the company’s stock worth $1,259,000 after purchasing an additional 162 shares in the last quarter. Finally, Veracity Capital LLC increased its stake in shares of AstraZeneca by 4.5% in the third quarter. Veracity Capital LLC now owns 3,833 shares of the company’s stock worth $299,000 after purchasing an additional 164 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

NASDAQ:AZN opened at $66.91 on Friday. The business’s 50-day moving average is $66.02 and its 200 day moving average is $74.62. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a market capitalization of $207.46 billion, a P/E ratio of 32.01, a P/E/G ratio of 1.05 and a beta of 0.46. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS. On average, equities research analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, AstraZeneca presently has an average rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.